The igf system in carcinogenesis and its implication for cancer therapy

Current Oncology

Volumn 18, Issue 6, 2011, Pages 301-302

  Yang, Shi Yu ^a   Winslet, M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INSM 18; INSULIN LIKE GROWTH FACTOR RECEPTOR 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; HOMEOSTASIS; HUMAN; LIVER CANCER; NEUROECTODERM TUMOR; PROSTATE CANCER; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT RESPONSE;

EID: 82955172948     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i6.885     Document Type: Article

References (17)

1. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007;92:4529-35.
2. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
3. Karamouzis MV, Papavassiliou AG. The igf-1 network in lung carcinoma therapeutics. Trends Mol Med 2006;12:595-602.
4. Durai R, Davies M, Yang W, et al. Biology of insulin-like growth factor binding protein-4 and its role in cancer. Int J Oncol 2006;28:1317-25.
5. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (igf)-i, igf binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
6. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 2009;15:225-33.
7. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the dna damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
8. Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci 2011;16:531-8.
9. Shiff SJ, Rigas B. Colon adenomatous polyps-do they grow inward? Lancet 1997;349:1853-4.
10. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
11. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-i receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-88.
12. Haluska P, Shaw HM, Batzel GN, et al. Phase i dose escalation study of the anti insulin-like growth factor-i receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
13. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-i receptor kinase inhibitor blocks insulin-like growth factor-i receptor signaling in vitro and inhibits insulin-like growth factor-i receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6:2158-67.
14. Yang SY, Sales KM, Fuller BJ, Seifalian AM, Winslet MC. Inducing apoptosis of human colon cancer cells by an igf-i D domain analogue peptide. Mol Cancer 2008;7:17.
15. Durai R, Yang SY, Sales KM, Seifalian AM, Goldspink G, Winslet MC. Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer. Int J Oncol 2007;30:883-8.
16. Durai R, Yang SY, Seifalian AM, Goldspink G, Winslet MC. Role of insulin-like growth factor binding protein-4 in prevention of colon cancer. World J Surg Oncol 2007;5:128.
17. Durai R, Yang SY, Sales KM, Seifalian AM, Goldspink G, Winslet MC. Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis 2007;9:625-31.